Zevra Therapeutics
ZVRA
110 hedge funds and large institutions have $272M invested in Zevra Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 13 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more ownership
Funds ownership: 63.56% → 65.55% (+2%)
1% more funds holding
Funds holding: 109 → 110 (+1)
4% less capital invested
Capital invested by funds: $283M → $272M (-$11.4M)
46% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $5.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
+$5.82M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.16M |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$4.9M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.78M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.9M |
| 2 |
ACM
Altium Capital Management
New York
|
-$4.47M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$3.07M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.44M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.44M |
ZVRA Hedge Fund Activity: Q1 2025 in Review
110 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2025, worth a combined $272M — down 4% from $283M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ZVRA positions and 13 closed out — a net gain of 2 holders — while 43 added to existing stakes and 30 trimmed.
The largest buyer was Legal & General Group, adding an estimated $5.82M. The largest seller was Nantahala Capital Management, cutting an estimated $6.9M.
- 110 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2025, up from 109 in Q4 2024.
- Funds reported $272M of Zevra Therapeutics stock for Q1 2025, down 4% quarter-over-quarter.
- 15 funds opened new Zevra Therapeutics positions in Q1 2025 and 13 closed out, a net change of +2 holders.
- The largest Zevra Therapeutics buyer in Q1 2025 was Legal & General Group, an estimated $5.82M added.
- The largest Zevra Therapeutics seller in Q1 2025 was Nantahala Capital Management, an estimated $6.9M sold.
Based on aggregated 13F filings for Q1 2025.